Bates M, Mullen D, Lee E, Costigan D, Heron EA, Kernan N, et al. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer. Pathol Res Pract. 2024;253(December 2023):155020.

Ryan E, Kelly L, Bates M. Altered Inflammasome and Immune activation in Paediatric Traumatic Brain Injury. Res Sq. 2024.

Logan JM, Hopkins AM, Martini C, Sorvina A, Tewari P, Prabhakaran S, et al. Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1. Cancers (Basel). 2023;15(12).

Mohamed BM, Ward MP, Bates M, Spillane CD, Kelly T, Martin C, et al. Ex vivo expansion of circulating tumour cells (CTCs). Sci Rep. 2023 Mar 6;13(1):3704.

Lazniewska J, Li KL, Johnson IRD, Sorvina A, Logan JM, Martini C, et al. Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression. Sci Rep. 2023;13(1):1–19.

Bates M, Mohamed BM, Ward MP, Kelly TE, O’Connor R, Malone V, et al. Circulating tumour cells: The Good, the Bad and the Ugly. Biochim Biophys Acta - Rev Cancer. 2023;1878(2):188863.

Kelly TE, Spillane CL, Ward MP, Hokamp K, Huang Y, Tewari P, et al. Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy. Front Cell Dev Biol. 2023 Dec 7;11(December):1–17.

Martini C, Logan JMJM, Sorvina A, Gordon C, Beck ARAR, S-Y. Ung B, et al. Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer. Pathology. 2023;55(1):40–51.

McShane R, Arya S, Stewart AJ, Caie PD, Bates M. Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma. Biochim Biophys Acta - Rev Cancer. 2021 Dec;1876(2):188598.

Ward MP, E. Kane L, A. Norris L, Mohamed BM, Kelly T, Bates M, et al. Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell? Mol Cancer. 2021;20(1).

Spillane CD, Cooke NM, Ward MP, Kenny D, Blackshields G, Kelly T, et al. The induction of a mesenchymal phenotype by platelet cloaking of cancer cells is a universal phenomenon. Transl Oncol. 2021;14(12).

Kalachand RD, O’Riain C, Toomey S, Carr A, Timms KM, O’Toole S, et al. Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer. Obstet Gynecol Sci. 2020;63(5).

Bates M, Spillane CDCDCD, Gallagher MFMF, McCann A, Martin C, Blackshields G, et al. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. Chan DW, editor. PLoS One. 2020 Dec 28;15(12):e0243715.

Annett S, Moore G, Short A, Marshall A, McCrudden C, Yakkundi A, et al. FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. Br J Cancer. 2020;122(3).

Bates M, Boland A, McDermott N, Marignol L. YB-1: The key to personalised prostate cancer management? Cancer Lett. 2020;490.

Bates M, Furlong F, Gallagher MFMF, Spillane CDCD, McCann A, O’Toole S, et al. Too MAD or not MAD enough: The duplicitous role of the spindle assembly checkpoint protein MAD2 in cancer. Cancer Lett. 2020 Jan 28;469:11–21.

White CMCM, Bakhiet S, Bates M, Ruttle C, Pilkington LJLJ, Keegan H, et al. Exposure to tobacco smoke measured by urinary nicotine metabolites increases risk of p16/Ki-67 co-expression and high-grade cervical neoplasia in HPV positive women: A two year prospective study. Cancer Epidemiol. 2020;68(August 2020):101793.

Mohamed B, Ward M, Bates M, Spillane C, Kelly T, Martin C, et al. 599 Circulating tumour cells in breast and ovarian cancer: size-based isolation and ex vivo expansion. In: Translational research. BMJ Publishing Group Ltd; 2020. p. A132.1-A132.

Ward MP, Mohamed BM, Kane L, Bates M, Berghoff J, Spillane CL, et al. Abstract 764: Influence of platelets and neutrophils on circulating tumour cells. Cancer Res. 2020 Aug 15;80(16_Supplement):764–764.

Perez E, Mohamed B, Di Capua D, Gleeson N, Thompson C, Abu Saadeh F, et al. High Expression Of Neuromedin U In High Grade Serous Ovarian Cancer Confers A Progression Free Survival Advantage. Mod Pathol. 2019;32(S2).

Ryan E, Kelly L, Duff E, Bates M, Bolger T, Molloy E. GP124 IL1-β levels at presentation correlate with symptom burden at 2 weeks in paediatric mild traumatic brain injury. Arch Dis Child. 2019;104:A80–1.

Ryan E, Duff E, Huggard D, Bates M, Doherty DG, Melo AM, et al. GP123 Altered systemic inflammatory response in paediatric mild traumatic brain injury. Arch Dis Child. 2019;104:A80.

Inder S, Bates M, Ni Labhrai N, McDermott N, Schneider J, Erdmann G, et al. Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance. Sci Rep. 2019;9(1).

Inder S, Bates M, McDermott N, Saluzzo J, Ní Labhraí N, Schneider J, et al. OC-0381: Lessons from isogenic models of radioresistant prostate cancer cells. Radiother Oncol. 2018;127:S194–5.

Inder S, Bates M, McDermott N, Domad J, Schneider J, Erdmann G, et al. Profiling of radioresistant prostate cancer cells identifies deregulation of key protein. Clin Transl Radiat Oncol. 2017;120(S2):24.

Ffrench B, Gasch C, Hokamp K, Spillane C, Blackshields G, Mahgoub TM, et al. CD10− /ALDH− cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy. Cell Death Dis. 2017 Oct 1;8(10).

Sulaiman G, Cooke A, Ffrench B, Gasch C, Abdullai OA, O’Connor K, et al. MyD88 is an essential component of retinoic acid-induced differentiation in human pluripotent embryonal carcinoma cells. Cell Death Differ. 2017;24(11).

White C, Bakhiet S, Bates M, Keegan H, Pilkington L, Ruttle C, et al. Triage of LSIL/ASC-US with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study. Cytopathology. 2016;27(4).

Bates M, Gubbins L, Mullen D, Lee E, Barry-O’Crowley, Jacqui; Costigan D, O’Riain C, et al. TLR4 and MAD2: Drivers of Chemoresistance in Ovarian Cancer. Lab Investig. 2016;96:276A-277A.

Bates M, Spillane C, Gallagher M, McCann A, O’Toole S, O’Leary J. The Role of the TLR4 Pathway and the Spindle Assembly Checkpoint in Ovarian Cancer Prognosis. J Pathol. 2015;237:S44–S44.

Bates M, Spillane C, Gallagher M, McCann A, O’Toole S, O’Leary J. The Role of MAD2 and MyD88 as Prognostic Indicators in Ovarian Cancer. J Pathol. 2015;237:S45.

D’Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O’Crowley J, et al. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. PLoS One. 2014 Jun 30;9(6).